EVENTIDE ASSET MANAGEMENT, LLC historic quarter change: USA Other Stocks, New
In shares no fund filing gives a ticker for, so this site has no page for them (listed in the US), over 21 quarters from 2013-12-31 to 2026-06-30, EVENTIDE ASSET MANAGEMENT, LLC opened 78 positions, added to 283, reduced 57 and sold out of 92.
- Q1 2026: Stock ALIGHT INC; Country of operation United States; Class COM CL A; Shares before 0.
- Q4 2025: Stock WAVE LIFE SCIENCES LTD; Country of operation —; Class SHS; Shares before 0.
- Q2 2025: Stock PINNACLE FINL PARTNERS INC; Country of operation United States; Class COM; Shares before 0.
- Q2 2024: Stock NEKTAR THERAPEUTICS; Country of operation United States; Class COM; Shares before 0.
Each consecutive pair of Form 13F-HR filings compared (SEC CIK 1442891), 21 quarters: Q2 2026 (2026-03-31 to 2026-06-30, filed 2026-08-14); Q1 2026 (2025-12-31 to 2026-03-31, filed 2026-05-15); Q4 2025 (2025-09-30 to 2025-12-31, filed 2026-02-13); Q3 2025 (2025-06-30 to 2025-09-30, filed 2025-11-14); Q2 2025 (2025-03-31 to 2025-06-30, filed 2025-08-14); Q1 2025 (2024-12-31 to 2025-03-31, filed 2025-05-15); Q4 2024 (2024-09-30 to 2024-12-31, filed 2025-02-14); Q3 2024 (2024-06-30 to 2024-09-30, filed 2024-11-14); Q2 2024 (2024-03-31 to 2024-06-30, filed 2024-08-13); Q1 2024 (2023-12-31 to 2024-03-31, filed 2024-05-15); Q3 2016 (2016-06-30 to 2016-09-30, filed 2016-11-14); Q2 2016 (2016-03-31 to 2016-06-30, filed 2016-08-15); Q1 2016 (2015-12-31 to 2016-03-31, filed 2016-05-16); Q4 2015 (2015-09-30 to 2015-12-31, filed 2016-02-16); Q3 2015 (2015-06-30 to 2015-09-30, filed 2015-11-13); Q2 2015 (2015-03-31 to 2015-06-30, filed 2015-08-14); Q1 2015 (2014-12-31 to 2015-03-31, filed 2015-05-14); Q4 2014 (2014-09-30 to 2014-12-31, filed 2015-02-12); Q3 2014 (2014-06-30 to 2014-09-30, filed 2014-11-12); Q2 2014 (2014-03-31 to 2014-06-30, filed 2014-08-14); Q1 2014 (2013-12-31 to 2014-03-31, filed 2014-05-13). Rows for the same security, class and put/call are added together. Value change is the filed value at each quarter end, so it includes the price move. Only the filings held here are compared; the firm's 13F-HR filings go back to the quarter ended 2013-12-31. Not compared, as a quarter between them is not held here yet: 2016-09-30 to 2023-12-31 (missing 2016-12-31, 2017-03-31, 2017-06-30, 2017-09-30, 2017-12-31, 2018-03-31, 2018-06-30, 2018-09-30, 2018-12-31, 2019-03-31, 2019-06-30, 2019-09-30, 2019-12-31, 2020-03-31, 2020-06-30, 2020-09-30, 2020-12-31, 2021-03-31, 2021-06-30, 2021-09-30, 2021-12-31, 2022-03-31, 2022-06-30, 2022-09-30, 2022-12-31, 2023-03-31, 2023-06-30, 2023-09-30).
| Quarter | Stock | Country of operation | Class | Shares before | Shares after | Share change | Value before | Value after | Value change | Filed |
|---|
| Q1 2026 | ALIGHT INC
CUSIP 01626W101 | United States | COM CL A | 0 | 18,661 | +18,661 | $0 | $10,407 | +$10,407 | 2026-05-15 |
|---|
| Q4 2025 | WAVE LIFE SCIENCES LTD
CUSIP Y95308105 | | SHS | 0 | 500,000 | +500,000 | $0 | $8,500,000 | +$8,500,000 | 2026-02-13 |
|---|
| Q2 2025 | PINNACLE FINL PARTNERS INC
CUSIP 72346Q104 | United States | COM | 0 | 4,579 | +4,579 | $0 | $501,946 | +$501,946 | 2025-08-14 |
|---|
| Q2 2024 | NEKTAR THERAPEUTICS
CUSIP 640268108 | United States | COM | 0 | 7,529,096 | +7,529,096 | $0 | $9,336,079 | +$9,336,079 | 2024-08-13 |
|---|
| Q1 2024 | ALPINE IMMUNE SCIENCES INC
CUSIP 02083G100 | United States | COM | 0 | 408,542 | +408,542 | $0 | $16,194,605 | +$16,194,605 | 2024-05-15 |
|---|
| Q3 2016 | MASONITE INTL CORP NEW
CUSIP 575385109 | | COM | 0 | 202,700 | +202,700 | $0 | $12,602,000 | +$12,602,000 | 2016-11-14 |
|---|
| Q3 2016 | AUDENTES THERAPEUTICS INC
CUSIP 05070R104 | | COM | 0 | 225,000 | +225,000 | $0 | $4,007,000 | +$4,007,000 | 2016-11-14 |
|---|
| Q2 2016 | ATLANTICA YIELD PLC
CUSIP G0751N103 | | SHS | 0 | 914,400 | +914,400 | $0 | $16,990,000 | +$16,990,000 | 2016-08-15 |
|---|
| Q2 2016 | WAVE LIFE SCIENCES LTD
CUSIP Y95308105 | | SHS | 0 | 380,000 | +380,000 | $0 | $7,862,000 | +$7,862,000 | 2016-08-15 |
|---|
| Q2 2016 | SYROS PHARMACEUTICALS INC
CUSIP 87184Q107 | | COM | 0 | 150,000 | +150,000 | $0 | $2,723,000 | +$2,723,000 | 2016-08-15 |
|---|
| Q2 2016 | TETRAPHASE PHARMACEUTICALS I
CUSIP 88165N105 | | COM | 0 | 600,000 | +600,000 | $0 | $2,580,000 | +$2,580,000 | 2016-08-15 |
|---|
| Q1 2016 | ESSA PHARMA INC
CUSIP 29668H104 | | COM | 0 | 2,719,410 | +2,719,410 | $0 | $7,826,000 | +$7,826,000 | 2016-05-16 |
|---|
| Q1 2016 | EPIZYME INC
CUSIP 29428V104 | | COM | 0 | 275,000 | +275,000 | $0 | $3,333,000 | +$3,333,000 | 2016-05-16 |
|---|
| Q1 2016 | PROTEOSTASIS THERAPEUTICS IN
CUSIP 74373B109 | | COM | 0 | 200,000 | +200,000 | $0 | $1,928,000 | +$1,928,000 | 2016-05-16 |
|---|
| Q1 2016 | ACCURAY INC
CUSIP 4397105 | | COM | 0 | 306,200 | +306,200 | $0 | $1,770,000 | +$1,770,000 | 2016-05-16 |
|---|
| Q1 2016 | BUNGE LIMITED
CUSIP G16962105 | United States | COM | 0 | 2,200 | +2,200 | $0 | $125,000 | +$125,000 | 2016-05-16 |
|---|
| Q4 2015 | JUNO THERAPEUTICS INC
CUSIP 48205A109 | | COM | 0 | 90,000 | +90,000 | $0 | $3,957,000 | +$3,957,000 | 2016-02-16 |
|---|
| Q4 2015 | COLUMBIA PIPELINE PARTNERS L
CUSIP 198281107 | | COM UT REPSTG | 0 | 6,700 | +6,700 | $0 | $117,000 | +$117,000 | 2016-02-16 |
|---|
| Q4 2015 | ITC HLDGS CORP
CUSIP 465685105 | | COM | 0 | 2,300 | +2,300 | $0 | $90,000 | +$90,000 | 2016-02-16 |
|---|
| Q3 2015 | TERRAFORM PWR INC
CUSIP 88104R100 | | CL A COM | 0 | 1,249,550 | +1,249,550 | $0 | $17,769,000 | +$17,769,000 | 2015-11-13 |
|---|
| Q3 2015 | SUNPOWER CORP
CUSIP 867652406 | United States | COM | 0 | 641,700 | +641,700 | $0 | $12,860,000 | +$12,860,000 | 2015-11-13 |
|---|
| Q3 2015 | KITE PHARMA INC
CUSIP 49803L109 | | COM | 0 | 140,000 | +140,000 | $0 | $7,795,000 | +$7,795,000 | 2015-11-13 |
|---|
| Q3 2015 | TERRAFORM GLOBAL INC
CUSIP 88104M101 | | CL A | 0 | 680,400 | +680,400 | $0 | $4,531,000 | +$4,531,000 | 2015-11-13 |
|---|
| Q3 2015 | TRACON PHARMACEUTICALS INC
CUSIP 89237H100 | | COM | 0 | 403,912 | +403,912 | $0 | $3,946,000 | +$3,946,000 | 2015-11-13 |
|---|
| Q3 2015 | 8POINT3 ENERGY PARTNERS LP
CUSIP 282539105 | | CL A RPT LTDPT | 0 | 334,100 | +334,100 | $0 | $3,545,000 | +$3,545,000 | 2015-11-13 |
|---|
| Q3 2015 | SERES THERAPEUTICS INC
CUSIP 81750R102 | United States | COM | 0 | 107,530 | +107,530 | $0 | $3,187,000 | +$3,187,000 | 2015-11-13 |
|---|
| Q3 2015 | BLUEPRINT MEDICINES CORP
CUSIP 09627Y109 | United States | COM | 0 | 107,000 | +107,000 | $0 | $2,283,000 | +$2,283,000 | 2015-11-13 |
|---|
| Q3 2015 | GLOBAL BLOOD THERAPEUTICS IN
CUSIP 37890U108 | | COM | 0 | 15,479 | +15,479 | $0 | $653,000 | +$653,000 | 2015-11-13 |
|---|
| Q3 2015 | JOHNSON CTLS INC
CUSIP 478366107 | | COM | 0 | 2,750 | +2,750 | $0 | $114,000 | +$114,000 | 2015-11-13 |
|---|
| Q3 2015 | SPECTRA ENERGY PARTNERS LP
CUSIP 84756N109 | | COM | 0 | 2,700 | +2,700 | $0 | $109,000 | +$109,000 | 2015-11-13 |
|---|
| Q3 2015 | SPECTRA ENERGY CORP
CUSIP 847560109 | | COM | 0 | 3,250 | +3,250 | $0 | $85,000 | +$85,000 | 2015-11-13 |
|---|
| Q3 2015 | NRG YIELD INC
CUSIP 62942X405 | | CL C | 0 | 5,100 | +5,100 | $0 | $59,000 | +$59,000 | 2015-11-13 |
|---|
| Q3 2015 | HCP INC
CUSIP 40414L109 | | COM | 0 | 1,470 | +1,470 | $0 | $55,000 | +$55,000 | 2015-11-13 |
|---|
| Q3 2015 | PATTERN ENERGY GROUP INC
CUSIP 70338P100 | | CL A | 0 | 2,050 | +2,050 | $0 | $39,000 | +$39,000 | 2015-11-13 |
|---|
| Q3 2015 | ABENGOA YIELD PLC
CUSIP G00349103 | | ORD SHS | 0 | 1,700 | +1,700 | $0 | $28,000 | +$28,000 | 2015-11-13 |
|---|
| Q3 2015 | NATIONAL INSTRS CORP
CUSIP 636518102 | United States | COM | 0 | 1,000 | +1,000 | $0 | $28,000 | +$28,000 | 2015-11-13 |
|---|
| Q3 2015 | HEALTH CARE REIT INC
CUSIP 42217K106 | | COM | 0 | 100 | +100 | $0 | $7,000 | +$7,000 | 2015-11-13 |
|---|
| Q2 2015 | MACQUARIE INFRASTRUCTURE COR
CUSIP 55608B105 | | COM | 0 | 633,700 | +633,700 | $0 | $52,363,000 | +$52,363,000 | 2015-08-14 |
|---|
| Q2 2015 | IMPERVA INC
CUSIP 45321L100 | | COM | 0 | 329,700 | +329,700 | $0 | $22,321,000 | +$22,321,000 | 2015-08-14 |
|---|
| Q2 2015 | QLIK TECHNOLOGIES INC
CUSIP 74733T105 | | COM | 0 | 521,300 | +521,300 | $0 | $18,225,000 | +$18,225,000 | 2015-08-14 |
|---|
| Q2 2015 | SEATTLE GENETICS INC
CUSIP 812578102 | | COM | 0 | 128,100 | +128,100 | $0 | $6,200,000 | +$6,200,000 | 2015-08-14 |
|---|
| Q2 2015 | RETROPHIN INC
CUSIP 761299106 | | COM | 0 | 165,100 | +165,100 | $0 | $5,473,000 | +$5,473,000 | 2015-08-14 |
|---|
| Q2 2015 | CASTLIGHT HEALTH INC
CUSIP 14862Q100 | | CL B | 0 | 550,600 | +550,600 | $0 | $4,482,000 | +$4,482,000 | 2015-08-14 |
|---|
| Q2 2015 | SPARK THERAPEUTICS INC
CUSIP 84652J103 | | COM | 0 | 38,200 | +38,200 | $0 | $2,302,000 | +$2,302,000 | 2015-08-14 |
|---|
| Q2 2015 | CIDARA THERAPEUTICS INC
CUSIP 171757107 | | COM | 0 | 122,628 | +122,628 | $0 | $1,719,000 | +$1,719,000 | 2015-08-14 |
|---|
| Q1 2015 | LAM RESEARCH CORP
CUSIP 512807108 | United States | COM | 0 | 350,900 | +350,900 | $0 | $24,645,000 | +$24,645,000 | 2015-05-14 |
|---|
| Q1 2015 | MOBILEYE N V AMSTELVEEN
CUSIP N51488117 | | ORD SHS | 0 | 493,800 | +493,800 | $0 | $20,754,000 | +$20,754,000 | 2015-05-14 |
|---|
| Q1 2015 | SANDISK CORP
CUSIP 80004C101 | | COM | 0 | 321,800 | +321,800 | $0 | $20,473,000 | +$20,473,000 | 2015-05-14 |
|---|
| Q1 2015 | INTEGRATED DEVICE TECHNOLOGY
CUSIP 458118106 | | COM | 0 | 776,100 | +776,100 | $0 | $15,538,000 | +$15,538,000 | 2015-05-14 |
|---|
| Q1 2015 | PROOFPOINT INC
CUSIP 743424103 | | COM | 0 | 239,900 | +239,900 | $0 | $14,207,000 | +$14,207,000 | 2015-05-14 |
|---|
| Q1 2015 | ZOSANO PHARMA CORP
CUSIP 98979H103 | | COM | 0 | 828,900 | +828,900 | $0 | $8,380,000 | +$8,380,000 | 2015-05-14 |
|---|
| Q1 2015 | IMMUNE DESIGN CORP
CUSIP 45252L103 | | COM | 0 | 81,957 | +81,957 | $0 | $1,730,000 | +$1,730,000 | 2015-05-14 |
|---|
| Q1 2015 | LOXO ONCOLOGY INC
CUSIP 548862101 | | COM | 0 | 114,600 | +114,600 | $0 | $1,427,000 | +$1,427,000 | 2015-05-14 |
|---|
| Q4 2014 | FIREEYE INC
CUSIP 31816Q101 | | COM | 0 | 575,600 | +575,600 | $0 | $18,177,000 | +$18,177,000 | 2015-02-12 |
|---|
| Q4 2014 | SPLUNK INC
CUSIP 848637104 | United States | COM | 0 | 156,400 | +156,400 | $0 | $9,220,000 | +$9,220,000 | 2015-02-12 |
|---|
| Q4 2014 | TESARO INC
CUSIP 881569107 | | COM | 0 | 75,000 | +75,000 | $0 | $2,789,000 | +$2,789,000 | 2015-02-12 |
|---|
| Q4 2014 | WPX ENERGY INC
CUSIP 98212B103 | | COM | 0 | 150,000 | +150,000 | $0 | $1,745,000 | +$1,745,000 | 2015-02-12 |
|---|
| Q4 2014 | REGULUS THERAPEUTICS INC
CUSIP 75915K101 | | COM | 0 | 60,000 | +60,000 | $0 | $962,000 | +$962,000 | 2015-02-12 |
|---|
| Q4 2014 | ZAFGEN INC
CUSIP 98885E103 | | COM | 0 | 600 | +600 | $0 | $19,000 | +$19,000 | 2015-02-12 |
|---|
| Q3 2014 | SAGE THERAPEUTICS INC
CUSIP 78667J108 | United States | COM | 0 | 40,200 | +40,200 | $0 | $1,266,000 | +$1,266,000 | 2014-11-12 |
|---|
| Q3 2014 | TANDEM DIABETES CARE INC
CUSIP 875372104 | | COM | 0 | 80,000 | +80,000 | $0 | $1,074,000 | +$1,074,000 | 2014-11-12 |
|---|
| Q3 2014 | AVALANCHE BIOTECHNOLOGIES IN
CUSIP 05337G107 | | COM | 0 | 20,000 | +20,000 | $0 | $684,000 | +$684,000 | 2014-11-12 |
|---|
| Q2 2014 | CELGENE CORP
CUSIP 151020104 | | COM | 0 | 190,000 | +190,000 | $0 | $16,317,000 | +$16,317,000 | 2014-08-14 |
|---|
| Q2 2014 | TABLEAU SOFTWARE INC
CUSIP 87336U105 | | CL A | 0 | 150,100 | +150,100 | $0 | $10,707,000 | +$10,707,000 | 2014-08-14 |
|---|
| Q2 2014 | APPLIED GENETIC TECHNOL CORP
CUSIP 03820J100 | | COM | 0 | 205,500 | +205,500 | $0 | $4,747,000 | +$4,747,000 | 2014-08-14 |
|---|
| Q2 2014 | ACCELERON PHARMA INC
CUSIP 00434H108 | | COM | 0 | 62,100 | +62,100 | $0 | $2,110,000 | +$2,110,000 | 2014-08-14 |
|---|
| Q2 2014 | DICERNA PHARMACEUTICALS INC
CUSIP 253031108 | | COM | 0 | 63,700 | +63,700 | $0 | $1,438,000 | +$1,438,000 | 2014-08-14 |
|---|
| Q2 2014 | VERSARTIS INC
CUSIP 92529L102 | | COM | 0 | 50,000 | +50,000 | $0 | $1,402,000 | +$1,402,000 | 2014-08-14 |
|---|
| Q2 2014 | ARROWHEAD RESH CORP
CUSIP 042797209 | | COM NEW | 0 | 80,000 | +80,000 | $0 | $1,145,000 | +$1,145,000 | 2014-08-14 |
|---|
| Q2 2014 | AEGERION PHARMACEUTICALS INC
CUSIP 00767E102 | | COM | 0 | 20,000 | +20,000 | $0 | $642,000 | +$642,000 | 2014-08-14 |
|---|
| Q2 2014 | VERASTEM INC
CUSIP 92337C104 | | COM | 0 | 20,900 | +20,900 | $0 | $189,000 | +$189,000 | 2014-08-14 |
|---|
| Q1 2014 | ROCKWOOD HLDGS INC
CUSIP 774415103 | | COM | 0 | 170,400 | +170,400 | $0 | $12,678,000 | +$12,678,000 | 2014-05-13 |
|---|
| Q1 2014 | FIVE PRIME THERAPEUTICS INC
CUSIP 33830X104 | | COM | 0 | 513,200 | +513,200 | $0 | $10,090,000 | +$10,090,000 | 2014-05-13 |
|---|
| Q1 2014 | CHIMERIX INC
CUSIP 16934W106 | United States | COM | 0 | 411,900 | +411,900 | $0 | $9,408,000 | +$9,408,000 | 2014-05-13 |
|---|
| Q1 2014 | VMWARE INC
CUSIP 928563402 | United States | CL A COM | 0 | 78,600 | +78,600 | $0 | $8,490,000 | +$8,490,000 | 2014-05-13 |
|---|
| Q1 2014 | ASPEN TECHNOLOGY INC
CUSIP 045327103 | | COM | 0 | 128,500 | +128,500 | $0 | $5,443,000 | +$5,443,000 | 2014-05-13 |
|---|
| Q1 2014 | CERNER CORP
CUSIP 156782104 | | COM | 0 | 36,800 | +36,800 | $0 | $2,070,000 | +$2,070,000 | 2014-05-13 |
|---|
| Q1 2014 | CLOVIS ONCOLOGY INC
CUSIP 189464100 | | COM | 0 | 28,300 | +28,300 | $0 | $1,960,000 | +$1,960,000 | 2014-05-13 |
|---|